News | February 17, 2022
Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
The construction is scheduled to begin in the third quarter of the calendar year 2022, with expected completion in early 2024
Apexxnar is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible for the majority of invasive disease and pneumococcal pneumonia
The entire integration and transition of the brands is expected to be completed by March 2022
These results will be presented on 17 February at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium
Launches a host of innovative products & solutions across the entire flexible packaging value chain in October - December 2021
It will open new frontier for south-to-south collaboration and innovation transfer
Bebtelovimab neutralizes Omicron as demonstrated by pseudo virus and authentic virus data
The three prequalified products are manufactured by the originator company, Roche, but the listings should pave the way for more companies coming forward to seek WHO prequalification
AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia
Subscribe To Our Newsletter & Stay Updated
